· Form D filing · Baseline
Reported sold as filed: $12,000,000 · Offering amount as filed: $12,000,000
SEC source checked 29 Oct 2026. This is the issuer’s historical filing, not a current valuation.
View original evidence ↗Adela, Inc.
On its website, the company describes its work as “Best-in-class technology. Tissue-free detection. Adela is advancing the field of epigenomics to transform how cancer is detected and monitored. By leveraging proprietary methylome analysis technology…”.
- Industry
- Biotechnology
- Tracked VC backers
- 0
Tracking coverage and points
Tracking coverage
A source check is on hold. Previous evidence is retained.
- Momentum +1 · Limited coverage
- The latest public index does not report a rank for this company.Index checked:
- Fundraising +2 · Limited coverage
- Verified filings recorded. Existing baseline history earns no points.SEC source checked:
- New VC +3 · Awaiting data
- No verified dated source evidence recorded.
- Completed exit +10 · Source check held
- Latest source check was held; no new exit evidence was confirmed.
Coverage describes public evidence. Points require a qualifying milestone after your pick.
Publicly documented VC backing
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
No tracked VC backing is recorded.